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Swine vesicular disease virus (SVDV) is an enterovirus of the Picornaviridae family that belongs to the coxsackievirus B
group. A number of antigenic sites have been identified in SVDV by analysis of neutralizing monoclonal antibody-resistant
mutants and shown to be exposed on the surface of the capsid. In this paper we have identified seven new immunodominant
antigenic regions in SVDV capsid proteins by a peptide scanning method, using a panel of sera from infected pigs. When
these antigenic regions were located in the capsid by using a computer-generated three-dimensional model of the virion, one
was readily exposed on the surface of the virus and the remaining sites were located facing the inner side of the capsid shell,
at subunit contacts, or in the interior of the subunit structure. © 2000 Academic PressINTRODUCTION
Swine vesicular disease virus (SVDV) is an enterovirus
of the Picornaviridae family. It causes a highly infectious
disease in pigs with lesions that are indistinguishable
from those caused by foot-and-mouth disease virus and
vesicular stomatitis virus: formation of vesicles on the
coronary band, interdigital spaces, and soles of the feet
causing lameness. Some pigs also show vesicles on the
snout, tongue, teats, and lips. Since the disease was first
identified in Italy in 1966 (Nardelli et al., 1968), many
outbreaks have been reported in several countries in
Asia and Europe (Brocchi et al., 1997; Graves, 1986).
Phylogenetic studies strongly support the concept that
SVDV is a recently evolved genetic sublineage of CV-B5,
of which it can be considered a subspecies. SVDV most
likely arose from CV-B5 in a single transfer event that
occurred sometime between 1945 and 1965 (Zhang et al.,
1999). The amino acid sequences of the structural pro-
teins of both viruses can be aligned collinearly, sharing
90 (VP4) to 96% (VP2) identity (Zhang et al., 1993).
The SVDV capsid is composed of 60 copies of each of
the four structural proteins, VP1, VP2, VP3, and VP4,
forming a T 5 1 icosahedral shell. Each capsid subunit
is formed upon assembly of one copy of VP0, VP1, and
VP3. VP0 is the precursor of VP2 and VP4, the latter being
associated with the interior surface of the capsid. The
external polypeptides, VP1, VP2, and VP3, share an eight-
stranded antiparallel b-barrel structure formed of
b-strands connected by exposed loops. This structure is1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 34-1-6202247. E-mail: ley@inia.es.
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76common in most picornaviruses and it has been shown
that neutralization epitopes are located mainly in the
loops and exposed on the capsid surface (Page et al.,
1988). During assembly, 12 pentamers, each made of five
subunits, associate with the RNA molecule to form the
virion.
The antigenic characterization of the viruses is neces-
sary to understand the immune mechanisms induced by
these infectious agents, which would be of great help in
the design of diagnostic methods and effective vaccines
against them and providing invaluable insights into stud-
ies of virus–host interactions and the virus life cycle.
Both B and T cells participate in the immune response
against viral infections by reacting with viral epitopes.
B-cell epitopes of picornaviruses have been character-
ized mainly by experiments with neutralizing monoclonal
antibodies and sequence analysis of neutralization-re-
sistant escape mutants (reviewed in Usherwood and
Nash, 1995). Two different studies have used this ap-
proach to identify neutralization sites in SVDV. In the first
study, five neutralization determinants, designated sites
1, 2a, 2b, 3a, and 3b, respectively, were identified (Kanno
et al., 1995). Site 1 maps in VP1 (residues 87 and 88),
sites 2a and 2b map in VP2 (residues 163 and 154,
respectively), site 3a spans VP1 (residues 272 and 275)
and VP3 (residue 60), and site 3b spans VP2 (residues 70
and 233) and VP3 (residues 73 and 76). These five sites
are analogous to poliovirus neutralization sites 1, 2, 3A,
3B, and 3C, respectively. The second study, using a
recent European isolate of SVDV, identifies two addi-
tional neutralization determinants, one in the C-terminus
of VP1 (residue 261) and other in the C-terminus of VP3
(residue 234) (Nijhar et al., 1999).
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77NOVEL ANTIGENIC REGIONS IN SVDV CAPSID PROTEINSAn alternative and complementary approach for the
mapping of B-cell epitopes is the use of libraries of
synthetic overlapping peptides. The peptide scanning
analysis of sera from natural or experimental infections
in permissive hosts allows the identification of antigenic
sites not revealed by studies with neutralization-resistant
mutants. By this technique, new antigenic sites have
been identified in other enteroviruses such as poliovirus
3 (Roivainen et al., 1991) and coxsackievirus A9 (Pulli et
l., 1998). Furthermore, the relative immunodominance of
he different epitopes identified can be evaluated by
eans of the strength and/or frequency of the recogni-
ion for each individual peptide.
In this paper we describe the use of a synthetic pep-
ide library to identify B-cell epitopes in the structural
olypeptides of SVDV. Furthermore, we have located
hese new epitopes in the virion by using a three-dimen-
ional computer model of the SVDV capsid.
RESULTS
xperimental sera
The reactivity of the synthetic peptides with anti-SVDV
ntibodies was first assessed by ELISA, using sera ob-
ained from pigs infected experimentally with four differ-
nt isolates (UKG/27/’72, SPA/1/’93, ITL R1076, and ITL/
/’93). The antigenicity was found to be associated
ainly with five regions, one in the N-terminus of VP1
peptides 1010–1030), one in VP2 (peptide 2051), and
hree in VP3 (peptides 3010–3030, 3060, and 3100–3130)
Fig. 1). Significant reactivities were also observed within
even additional regions, four of them in VP1 (peptides
110, 1140–1150, 1210, and 1250), two in VP2 (peptides
091–2111 and 2141), and one in VP3 (peptides 3200–
210) (Fig. 1). Although some peptides were widely rec-
gnized by sera from animals inoculated with all the
trains (peptides 3100–3130, 2051, and 2091–2111), the
eptides most strongly recognized showed some kind of
pecificity for the isolate used in the inoculation of pigs.
hus, only sera from animals inoculated with SPA/1/’93
r ITL/9/’93 (SPA.30, IT-1.14, IT-2.14) reacted with peptides
orresponding to the N-terminus of VP1 (1010–1030),
hereas sera from animals inoculated with UKG/27/’72
r ITL R1076 (UK.21, ITr-1.22, ITr-2.29) did not react at all
ith these peptides. Significant reactions to at least one
eptide of the N-terminal region of VP3 (peptides 3010–
030) were found in all the sera except those infected
ith the isolate ITL R1076, whereas the opposite was
bserved for peptide 3060, which was recognized
trongly by the ITL R1076-induced sera, but very weakly
y sera to the other three isolates.
The highest antibody reactivity for sera SPA.30, IT-1.14,
nd IT-2.14 was observed against the N-terminus of VP1
Fig. 1). However, this region was not recognized at all by
he other sera. Sequence analysis of this region shows
igh variability between SVDV isolates (Zhang et al.,
p
p999). Isolates SPA/1/’93 and ITL/9/’93 are identical in
his region, but they differ from UKG/27/’72 in 6 amino
cid positions within the first 20 amino acid residues. To
est whether these substitutions could account for the
ifferences in reactivity observed, we synthesized a pep-
ide consisting of amino acids 1 to 20 of VP1, based on
he amino acid sequence of the UKG/27/’72 isolate, and
ompared the binding of antibodies from sera SPA.30,
T-1.14, IT-2.14, and UK.21 to both UKG/27/’72- and SPA/
/’93-derived peptides. As shown in Fig. 2, in all cases
he binding of the homotypic sequence (i.e., the se-
uence of the isolate used for the experimental infection
f the corresponding serum) was higher than the recog-
ition of the heterotypic peptide. In addition, in the IT-1.14
nd SPA.30 sera, in which both peptides are recognized,
competition experiment was performed using both
FIG. 1. Peptide scanning analysis of six different sera from pigs
infected experimentally with SVDV (serum SPA.30, taken 30 days after
infection with SPA/1/’93 isolate; sera IT-1.14 and IT-2.14, taken 14 days
after infection of two pigs with ITL/9/’93 isolate; serum UK.21, taken 21
days after infection with UKG/27/’72 isolate; and sera ITr-1.22 and
ITr-2.29, taken 22 and 29 days after infection of two pigs with Italy R1076
isolate and a normal pig serum as control (C). Each peptide is num-
bered on the basis of the position of its 10th (middle) amino acid in the
corresponding structural subunit, by using the four-digit code (i.e.,
peptide 4010 spans residues 1–20 of VP4). Each bar represents the OD
obtained for each single peptide in the ELISA described under Mate-
rials and Methods using a 1:100 dilution of each sera. Similar results
were obtained using a 1:250 dilution of sera (not shown).eptides, showing that, in each case, the homotypic
eptide was a better competitor (not shown).
78 JIME´NEZ-CLAVERO ET AL.Field sera
We examined the reactivity of the peptides with a
collection of field serum samples (Fig. 3). A first screen-
ing was performed with a pool of 21 sera from pigs
infected during a recent SVDV outbreak that showed
symptoms of the disease and had anti-SVDV antibodies
as determined by competition ELISA and VNT. This pool
confirmed most of the antigenic regions found with the
experimental sera, particularly those defined with pep-
tides 1010–1030, 1210, 1240–1250 in VP1, 2051 and 2091–
2111 in VP2, and 3060, 3110–3130, and 3190–3210 in VP3.
However, three additional regions not revealed with the
sera from experimental infections were found to be an-
tigenic for this pool of sera. These corresponded to
peptides 1180, 2001–2011, and 4010–4020. In contrast,
some peptides reacting with some of the experimental
sera did not react with this pool (peptides 1110, 1140–
1150, 2141, and 3010–3030).
We then analyzed individually 12 serum samples from
field SVD outbreaks. Figure 3 shows the pattern and the
degree of recognition of the peptides by these sera. The
results varied largely, some of them showing strong
reactions to most of the antigenic regions described
above and other sera giving weak reactions to a small
number of peptides or even no reaction at all. In general,
FIG. 2. Differential antibody binding of four experimental sera (UK.21,
SPA.30, IT-1.14, IT-2.14) by ELISA (see Materials and Methods) using
peptides based on the amino acid sequence of the N-terminal 20
residues of VP1 (peptide 1010), derived from the sequence of two
isolates: (E) UKG/27/’72 (GPPGEVMGRAIARVADTIGS) or (F) SPA/1/’93
(GPPGGVTEGIIARVADTVGS). The name of the corresponding serum is
indicated in each plot. SPA.30 was from a pig infected with SPA/1/’93
SVDV isolate; UK.21 was from an infection with UKG/27/’72 SVDV
isolate. The other two sera (IT-1.14, IT-2.14) were from pigs infected with
ITL/9/’93 SVDV isolate, whose amino acid sequence in the N-terminus
of VP1 is identical to that of the SPA/1/’93 isolate.the sera from animals showing symptoms of the disease
(sera S1–S4) gave stronger reactions in the peptidescanning ELISA than those from asymptomatic animals
(sera A1–A4). Four sera, all from asymptomatic pigs, did
not react with any peptide and are not represented in the
figure. As expected, positive field sera recognized pep-
tides that were also strongly recognized by the experi-
mental sera and/or by the pool of SVDV-positive field
sera, particularly peptides 1010–1030, 1170–1180, 1210,
and 1240–1250 in VP1, 2051, 2091, and 2141 in VP2, and
3010–3030, 3060, and 3100–3130 in VP3. To a lesser
extent, but significantly, some sera also reacted with
peptides 4010–4020, 2001–2011, 2241, 3210, and 1070–
1080.
Figure 4 shows a picture of the relative immunodomi-
nance of the different antigenic regions in each capsid
protein, which was obtained in two ways. First, the sums
of the absorbances obtained with the different peptides
with 14 individual sera were compared (Fig. 4A). Second,
FIG. 3. Peptide scanning analysis of different sera from field SVDV
outbreaks. Each bar represents the OD obtained for each single pep-
tide in the ELISA described under Materials and Methods. From top to
bottom (black bars), pool of SVDV-positive field sera (n:21), four sera
from symptomatic animals (S1–4), and four sera from asymptomatic
animals (A1–4). In each plot, the peptide scanning analysis of a pool of
20 SVDV-negative field sera (white bars) is included as a control of the
background for each peptide under field conditions. Each bar repre-
sents the OD obtained for each single peptide in the ELISA described
under Materials and Methods using a 1:100 dilution of each serum.
Similar results were obtained using a 1:250 dilution of sera (not shown).
Horizontal lines below the bars represent the peptides recognized by
experimentally infected animals as shown in Fig. 1.
79NOVEL ANTIGENIC REGIONS IN SVDV CAPSID PROTEINSthe strength (OD) and frequency of the recognition of
each peptide by all the sera analyzed, using an arbitrary
cut-off point, were scored (Fig. 4B). The best scores, as
well as the higher OD sums, were those obtained with
seven peptides: 2051, 2091, 3020, 3060, 3110, 1010, and
1210. These peptides define seven immunodominant re-
gions of the SVDV capsid (regions 1–7, Table 1). Five
secondary antigenic sites, on the basis of the frequency
and strength of the recognition, were also identified.
These were defined by peptides 4010–4020, 2141, 2241,
3210, and 1240–1250.
Location of immunodominant B-cell epitopes in the
capsid
The location of the seven immunodominant regions
defined by antibody binding to synthetic peptides on the
three-dimensional model of SVDV capsid is shown in Fig.
5. Two of these antigenic regions, namely regions 4 and
7, are significantly exposed at the exterior surface of the
capsid. Region 4 is the most exposed and overlaps with
neutralization site 3a, in the VP3 “knob.” Region 7 is only
partially exposed on the capsid (Figs. 5A, 5C, and 5E).
Regions 1 and 6 are located clearly at the interior surface
of the capsid (Figs. 5B and 5F). Regions 2 and 3 are
located at subunit contacts; thus they are exposed on the
subunit structure but not on the assembled capsid. Re-
gion 5 represents the region of a-helix A and b-strand D
of VP3, in the interior of the subunit; thus it is not exposed
on the surface of the capsid.
DISCUSSION
FIG. 4. Immunodominance analysis of the SVDV structural region by
peptide scanning. (A) Specific ELISA OD sums, obtained by subtracting
the conjugate control values from the primary readings of 14 individual
sera (SPA.30, IT-1.14, IT-2.14, UK.21, ITr-1.22, ITr-2.29, S1, S2, S3, S4, A1,
A2, A3, and A4). (B) Recognition frequency and strength of peptides of
14 sera (the same as in (A)) scored as follows: serum reactions with a
given peptide were arbitrary scored weak (1), strong (2), or very strong
(3), when OD was above 0.5, 1.0, and 1.5 OD units, respectively.The identification of antigenic sites of SVDV involved in
neutralization has been previously achieved by experi-ments with neutralizing monoclonal antibodies and se-
quence analysis of neutralization-resistant escape mu-
tants (Kanno et al., 1995; Nijhar et al., 1999). Monoclonal
antibody-escape mutants provide a powerful tool for
these analyses; however, their use has several limita-
tions. First, the immunogen used for generating virus-
neutralizing antibodies is often a highly purified prepa-
ration of virus particles. These viruses are obtained from
cell cultures usually in an advanced stage of infection.
Thus, other viral structures that could be targets for
antibody recognition and, eventually, for virus neutraliza-
tion in vivo are not represented in these preparations. In
addition, monoclonal antibodies are usually prepared in
mice, which are not permissive for virus infection. All
these factors could bias the immune response toward
epitopes that are readily exposed on the surface of the
virion in the particular conformation displayed by the
purified virus particles. On the other hand, the structure
of picornavirus capsids is dynamic and undergoes con-
formational changes upon binding to cellular receptors
and uncoating (Fricks and Hogle, 1990; Roivainen et al.,
1993; Ketterlinus and Wiegers, 1994; Li et al., 1994).
These changes may expose new antigenic sites missed
by classic monoclonal antibody escape mutant analysis.
Finally, the resultant mutations introduced in the escape
mutants virus must be viable. Thus, epitopes located at
sites such as the receptor-binding site are rarely identi-
fied by this analysis.
To complement the existing studies of the antigenic
characterization of SVDV, we have applied peptide scan-
ning analysis to identify novel antigenic regions in the
capsid polypeptides of the virus, as defined by synthetic
peptides that are recognized by SVDV-specific pig sera.
In this way we have identified seven major and five
secondary antigenic regions on the SVDV capsid.
It is remarkable that only one major antigenic region
(VP3 3051–3070, region 4) and one secondary antigenic
region (VP2 2232–2251) overlap with neutralization sites
defined previously for this virus (Kanno et al., 1995; Nijhar
et al., 1999): site 3a in VP3 (amino acid position 3060) and
site 3b (amino acid position 2233) in VP2, respectively.
These results are expected, considering the discontinu-
TABLE 1
Immunodominant Regions in SVDV Capsid Proteins
Identified by Peptide Scanning
Antigenic
region Protein
Residues
involved
Most reactive
peptide
1 VP2 2042–2061 2051
2 VP2 2082–2121 2091
3 VP3 3001–3040 3020
4 VP3 3051–3070 3060
5 VP3 3091–3120 3110
6 VP1 1001–1040 1010
7 VP1 1201–1220 1210
logous
80 JIME´NEZ-CLAVERO ET AL.ous nature of most neutralization sites found in picorna-
viruses, which span more than one capsid subunit. Pep-
tides 1080 and 1090, overlapping with neutralization site
1, did not show significant reactivity with most of the sera
FIG. 5. Location of the antigenic sites, numbered as in Table 1, on a
of SVDV from the outside or from the inside of the capsid, respectively.
subunit, respectively. (E and F) The pentamer structure (five subunits
respectively. Blue, VP1; green, VP2; red, VP3; orange, VP4. Note that in
of VP1, which are part of antigenic region 6, are not resolved, probably
happens in the crystal structure of coxsackievirus B3 and other homo
model.tested in the pepscan. This site is located in the BC loop
of VP1, a prominent region in the three-dimensionalstructure of the virus (Kanno et al., 1995). Although ap-
parently continuous, the spatial conformation of the BC
loop might influence the affinity of antibodies to this site.
Alternatively, other positions outside the BC loop of VP1
imensional model of the SVDV capsid. (A and B) The subunit structure
D) The subunit structure from the right side or from the left side of the
the fivefold axis), from the outside and from the inside of the capsid,
odel the spatial coordinates of the 12 N-terminal amino acid residues
the relative mobility and lack of secondary structure of this region, as
structures of picornaviruses used as templates for building the SVDVthree-d
(C and
around
this m
due tocould contribute to the binding affinity of site 1 to neu-
tralizing antibodies. In particular, the new neutralization
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81NOVEL ANTIGENIC REGIONS IN SVDV CAPSID PROTEINSsite found in the C-terminal region of VP1 locates in the
vicinity of site 1 in a three-dimensional model of the
capsid (Nijhar et al., 1999), suggesting that this site could
e composed of at least two distinct epitopes (Nijhar et
l., 1999).
Although peptide scanning analysis is thought to de-
ect only linear epitopes, it has been proposed that dis-
rete parts of discontinuous epitopes could be mimicked
y synthetic peptides (Van Regenmortel, 1988). Thus,
articular regions of the nonlinear epitopes might be
dentified by pepscan. This could explain the reactivity
ound in peptide scanning with the peptides covering
arts of the neutralization sites 3a and 3b.
The peptide scanning techniques have been used to
dentify B-cell epitopes on coxsackievirus A9 (Pulli et al.,
998) and poliovirus type 3 (Roivainen et al., 1991). All
hese viruses belong to the enterovirus genus and share
elated secondary, tertiary, and quaternary capsid pro-
ein structures. Coxsackievirus A9 shares 73% amino
cid identity with SVDV in the capsid proteins, and both
luster in the same enteroviral subgroup of coxsackie
-like viruses (Poyry et al., 1996). In coxsackievirus A9,
ive antigenic regions have been identified by pepscan
nalysis, namely, the N-termini of VP1 and VP3, the
-terminus of VP1, and the VP3 knob and VP2 “puff”
egions. We have found that the homologous regions in
VDV were also antigenic, and some of them, in partic-
lar the N-termini of VP1 and VP3 and the VP3 knob
corresponding to peptide 3060), were strongly reactive.
n addition, some of these regions (the N- and C-termini
f VP1) were antigenic in poliovirus type 3, using human
era from vaccinated individuals (Roivainen et al., 1991).
Consistent with what we found in SVDV, the peptide
canning analysis of the capsid proteins of poliovirus
ype 3 showed that the peptides recognized more fre-
uently and strongly by antibodies from vaccinated indi-
iduals did not map in the regions involved in the induc-
ion of neutralizing antibodies to poliovirus in experimen-
al animals. In addition, neutralization sites mapped in
oliovirus by neutralization-resistant mutants were only
eakly recognized or not recognized at all in the pep-
can (Roivainen et al., 1991).
Some of the antigenic regions identified in the pep-
can analysis of SVDV were recognized strongly by
ome sera, but weakly or not at all by other sera. This
as particularly evident for the N-terminal region of VP1,
hich shows high amino acid variability between iso-
ates (Zhang et al., 1999). Using peptides from this region,
ut based on the sequence of two different isolates, we
ave demonstrated that the discrepancies found in anti-
ody recognition of these peptides with different sera
an be attributed to isolate-specific antibody responses.
Location of the immunodominant regions identified by
eptide scanning in a three-dimensional model of SVDVevealed that only two sites (regions 4 and 7) were
ccessible from the outside of the viral capsid. The rest
4
sere exposed at the internal surface of the capsid shell
regions 1 and 6), at subunit contacts (regions 2 and 3),
r even inside the subunit tertiary structure (antigenic
egion 5). This result indicates that capsid protein pre-
ursors and dissociated subunits may induce antibodies
o SVDV during the infection in the natural host. On the
ther hand, alternative conformations of the intact virion
ould also play a role in the induction of antibodies. In
articular, the N-terminus of VP1, which is internal in the
apsid, becomes externalized upon binding to the cellu-
ar receptor of a variety of picornaviruses including po-
iovirus (Fricks and Hogle, 1990) and human rhinovirus
Hadfield et al., 1997). Furthermore, there is evidence of
n equilibrium between two alternative conformations of
he poliovirus virion, prior to interaction with the cells,
ne in which the N-terminus of VP1 is hidden and an-
ther in which it emerges to the surface (Roivainen et al.,
993; Li et al., 1994). In addition, the inhibition of picor-
avirus by antiviral compounds that act as “pocket fac-
ors” (Pevear et al., 1989; Andries et al., 1992; Phelps and
Post, 1995) suggests that a conformational change in the
capsid is necessary for infection. It was noted above that
antibodies to this region are common not only in SVDV-
infected animals, but also in humans vaccinated with
poliovirus attenuated (Sabin) vaccine and in rabbits in-
oculated with coxsackievirus A9. Further work will be
directed to assess the immunogenic potential of the
N-terminal region of SVDV VP1 and its role in infection.
MATERIALS AND METHODS
Serum samples
Experimental sera. Sera IT-1.14, IT-2.14, UK.21, ITr-1.22,
ITr-2.29, and SPA.30 were obtained from pigs infected
experimentally with different isolates of SVDV, after 14,
14, 21, 22, 29, and 30 days of infection, respectively.
IT-1.14 and IT-2.14 sera were from two pigs infected i.d.
with 106 TCDI50 units of ITL/9/’93 SVDV isolate; UK.21 is a
reference serum for SVD diagnosis, prepared at the
Institute for Animal Health, Pirbright, using the UKG/27/
’72 SVDV isolate. ITr-1.22 and ITr-2.29 were collected
from pigs inoculated i.v. with 108.5 TCDI50 of Italy R1076
SVDV isolate (Brocchi et al., 1995) and kindly provided by
Dr. E. Brocchi (IZSLE, Brescia, Italy). SPA.30 was ob-
tained similarly, from a pig inoculated with a single dose
of 107 TCDI50 of the Spanish SVDV strain SPA/1/’93 and
rovided by Dr. C. Gomez-Tejedor (CISA–INIA, Madrid,
pain). Normal pig serum obtained from a healthy pig
as used as control.
Field serum samples. Field sera were kindly provided
y Dr. E. Brocchi (IZSLE, Brescia, Italy). Twelve anti-SVDV
ositive field sera and a pool of 21 anti-SVDV positive
ield sera, tested by blocking ELISA and confirmed by
NT, were analyzed. The pool of SVDV-positive sera andof the field positive serum samples were from pigs
howing clinical symptoms of the disease during an
82 JIME´NEZ-CLAVERO ET AL.SVDV outbreak. The remaining sera corresponded to
nonsymptomatic pigs detected in five different herds
under the Italian National Serologic Surveillance Pro-
gram for SVD. Negative field sera (n:20) were collected
from clinically healthy animals of the same area and
pooled for use as control.
Peptides
Partially overlapping peptides (20-mer, 10-residue
overlap) were synthesized according to the amino acid
sequence of the structural region of the SVDV SPA/1/’93
isolate (unpublished data, GenBank Accession No.
AFO39166). Synthesis was achieved using FMOC chem-
istry on a multiple-peptide synthesis block (BT7400, Bio-
tech Instruments Ltd., UK). Sequential coupling of FMOC
amino acids (Novabiochem) onto the preloaded Wang
resins (Novabiochem) was conducted in the presence of
diisopropylcarbodiimide and hydroxybenzotriazole
(Sigma Chemical Co.). The peptides were cleaved from
the resin and side chain deprotected in the presence of
trifluoroacetic acid (using mix B, Applied Biosystems
Cleavage manual). Following precipitation with diethyl
ether, the individual peptides were dissolved in 5% acetic
acid and lyophilized. The resulting residues were dis-
solved in deionized water, semipurified using C18 Sep
Paks (Millipore), and lyophilized. The peptides were syn-
thesized in three batches, corresponding to the se-
quences of VP0, the precursor for capsid proteins VP4
and VP2 (32 peptides), VP3 (23 peptides), and VP1 (28
peptides).
Peptides were numbered by using the four-digit code
of their 10th amino acid in the corresponding structural
subunit. As one of the batches was designed based on
the VP0 precursor, one of the peptides contained a fu-
sion sequence consisting of the last 9 amino acid resi-
dues of VP4 and the 11 first amino acid residues of VP2.
It was named, however, peptide 2001 since its 10th
amino acid residue was the first of the VP2 chain.
Peptide ELISA
ELISA plates (Immulon 4HBX, Dynatech) were coated
with 2 mg/well of each peptide in distilled water by
dessication at 37°C, washed once with distilled water,
and blocked with 1% bovine serum albumin in PBS for 1 h
at 37°C. After removal of the blocking solution, the serum
samples were incubated at 1:100 or 1:250 dilution in PBS
with 1% bovine serum albumin (100 ml/well) for 1 h at
room temperature. The plates were then washed with
0.1% Tween 20 in PBS (PBS–Tween), and a secondary
horseradish peroxidase-conjugated anti-swine immuno-
globulin antibody (DAKO) was added at 1:6000 in PBS–
Tween. The plates were washed with PBS–Tween and
the color was developed with tetramethyl-benzidine. The
reaction was stopped with 2 M H2SO4, and the absor-bance at 450 nm was recorded with a multiscan plate
reader.
Modeling of the three-dimensional structure of SVDV
capsid proteins
The SWISS-MODEL server (Guex and Peitsch, 1997;
Peitsch, 1997) (http://www.expasy.ch/swissmod/SWISS-
MODEL.html) was used to model the structure of capsid
protein subunits. Using the BLASTP2 program (Altschul
et al., 1990) the server searched the database for homol-
ogies to SVDV protein sequences with known 3D struc-
ture. The structure database used by SWISS-MODEL is
derived from the Brookhaven Protein Data Bank (PDB,
BNL). Each protein chain of the database was placed in
an individual file, whose name was modified according
to the rule Chain Number-PDBCODE. Four main do-
mains, corresponding to the four structural chains of the
virus capsid, were separately modeled using the SIM
program (Huang and Miller, 1991) to select the templates
with significant identities along the sequence. Different
3D structures were used as templates in the comparative
protein modeling process using the program ProModII
(Peitsch, 1996). The following PDB entries were used to
perform the modeling of each protein: VP4 was modeled
using the first chain of the 11cov (coxsackievirus B3, 81%
identity), 12eah (poliovirus 2, 51%), 12plv (poliovirus 1,
50%), 11rhi (rhinovirus 3, 45%), and 11hri (rhinovirus 14,
44%); VP2 was modeled using 21cov (coxsackievirus B3,
84%), 22hwb (rhinovirus 14, 55%), 21hri (rhinovirus 14,
55%), 22plv (poliovirus 1, 46%), and 21eah (poliovirus 2,
46%); VP3 was modeled using 31cov (coxsackievirus B3,
85%), 32plv (poliovirus 1, 56%), 31eah (poliovirus 2, 56%),
31pov (poliovirus 1, 56%), and 31hri (rhinovirus 14, 48%);
and VP1 was modeled using 41cov (coxsackievirus B3,
82%), 42plv (poliovirus 1, 72%), 41rhi (rhinovirus 3, 70%),
41hri (rhinovirus 14, 68%), and 41eah (poliovirus 2, 65%).
Finally, the Gromos96 program (Van Gunsteren et al.,
1995) determined energy minimization of all models.
Some additional programs were used to check the qual-
ity of the model. PROCHECK (Laskowski et al., 1993) was
used to assess the stereochemical quality of the model
(Morris et al., 1992). The program average was 20.13
(ideally scores should be above 20.5). Bond angles and
bond lengths, checked by the WHAT IF program (Vriend,
1990), were found to deviate normally from the mean in
the normal value distribution for protein residues (Engh
and Huber, 1991). Results from the checking process can
be obtained from the following Web site: http://www.
cnb.uam.es/;cnbprot/svdv/check.html.
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